Advertisement

Scientific Interchange & Workshop


Exploring Recent Updates in the Treatment of Breast Cancer

November 16th 2022

Best Practices for Managing Tyrosine Kinase Inhibitor-Related Adverse Events

October 21st 2022

Exploring the Role of Antibody Drug Conjugates in Non-Small Cell Lung Cancer

October 19th 2022

Best Practices Along the Tissue Journey in NSCLC

October 12th 2022

The Evolving Treatment Landscape in Relapsed/Refractory Follicular Lymphoma

September 29th 2022

Clinical Scenarios: Treatment Decisions in Non-Small Cell Lung Cancer

August 30th 2022

Practical Approaches to Treatment in Breast Cancer

August 16th 2022

Translating Evidence to Clinical Practice to Improve Outcomes in Patients with Small Cell Lung Cancer

August 16th 2022

Exploring Recent Developments in the Treatment of Patients with HR+ Metastatic Breast Cancer

August 4th 2022

Bruton Tyrosine Kinase (BTK) Inhibitors in Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia

August 2nd 2022

Practical Approaches to Treatment in Patients with Breast Cancer

July 6th 2022

Clinical Scenarios: Treating Patients with Gastric Cancer

July 6th 2022

Sponsored by Daiichi Sankyo. Content independently developed by OncLive®.

Multidisciplinary Management of Patients with Basal Cell Carcinoma

June 16th 2022

New Directions in CLL

May 15th 2022

Treatment Decisions in Non-Small Cell Lung Cancer

April 6th 2022

Evolving Approaches in the Treatment of AML and MDS

March 25th 2022

Sponsored in part by Servier Pharmaceuticals. Content independently developed by OncLive.

HER2 Biomarker Testing in Breast and Gastrointestinal Cancers: The Role of the Pathologist

February 25th 2022

Funding from Daiichi Sankyo; Content Developed Independently by OncLive.

Current and Emerging Trends in Breast Cancer: HER2+ and HER2-Low

February 25th 2022

Funding from Daiichi Sankyo; Content Developed Independently by OncLive.

Treatment Updates and Advances in Cervical Cancer

February 7th 2022

Current and Emerging Trends in Breast Cancer: HER2 + and HER2-Low: An OncLive® Scientific Interchange and Workshop

January 21st 2022

Sponsored in part by Daiichi Sankyo. Content independently developed by OncLive®


Advertisement
Advertisement